# **:::** medidata

## Medidata RTSM for Direct-to-Patient

As the healthcare industry continues to deepen its focus on patient-centricity, the popularity of Direct-to-Patient (DtP) services in the clinical trial setting has grown significantly. The DtP approach brings investigational medicinal products (IMP) directly to a patient's home, bypassing the need for the patient to travel directly to a site. The benefits of this are:

- Patients are able to access customized care and novel therapies from the comfort of their homes
- Biopharmaceutical companies are able to facilitate patient enrollment and increase patient adherence, which are central to the success of clinical trials



Randomization and Trial Supply Management (RTSM) solutions play a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients' homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges, while ensuring that **the right treatment reaches the right patient at the right time**.

Given the changing dynamics of clinical trials and the demand for more patient centric approaches, Medidata now d supports Direct-to-Patient (DtP) shipments. With Medidata's Rave RTSM, sponsors and CROs canmanage DtP shipments for clinical trials or medical device trials, all while maintaining patient confidentiality since patient addresses are never stored in Rave RTSM.

Since virtual or DtP trials require agility in visit scheduling, **visits may be marked in the study configuration as home visits and/or at the site, so that kits can be sent directly to the patient using the Depot/Central Pharmacy inventory.** When Direct-to-Patient dispensation is processed in Rave EDC, a shipment request is raised with the configured DtP depot to request a patient/visit specific dispensation including the Subject Identifier so the depot can ship or courier the items to the patient.

Key features of Rave RTSM for DtP use are:

- Use in new and existing studies
- Flexibility in making mid-study changes
- Individual visits can be set to Direct-to-Patient through the Treatment Schedule
- Configurability on the visit and site level

### **:::** medidata

# **:::** medidata

FACT SHEET MEDIDATA RTSM FOR DIRECT-TO-PATIENT

- Dispense from site or directly generate a shipment from depot
- Manual dispensations are sourced from site inventory
- Sites can be configured to follow the DtP visit schedule, or to dispense from site inventory, supporting a trial combining virtual and physical sites
- Full lifecycle view of DtP shipments and dispensations (e.g., depot to patient, site accountability, site to destruction depot)



#### About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data.

Medidata, a Dassault Systèmes company (Euronext Paris: #13065, <u>DSY.PA</u>), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at <u>www.medidata.com</u> and follow us @medidata, The Operating System for Life Sciences™.

Medidata, Medidata Rave and Acorn AI are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes. info@medidata.com | +1 866 515 6044

#### Medidata Rave Clinical Cloud™

Cloud-based clinical research solutions | Innovative technology | Data-driven analytics Reduced costs | Improved time to market | Faster decisions | Minimized risk

#### **:::** medidata